drugset / Trial / NCT03274375
Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis
Phase 2
Completed
20 enrolled
Assistance Publique - Hôpitaux de Paris
URC-CIC Paris Descartes Necker Cochin · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to assess the efficacy of immunoadsorption therapy (IA) on improving the neurological status of severe pediatric anti-NMDAR encephalitis patients.
Timeline
- Start
- 2021-06-23
- Primary completion
- 2023-10-26
- Completion
- 2025-10-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Rituximab | Monoclonal antibody | — | — |